AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00157-07v1
51/9/3240    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calatayud, L.
Right arrow Articles by Liñares, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calatayud, L.
Right arrow Articles by Liñares, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3240-3246, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00157-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain{triangledown}

Laura Calatayud,1,2 C. Ardanuy,1,2 E. Cercenado,2,3 A. Fenoll,4 E. Bouza,2,3 R. Pallares,2,5 R. Martín,1 and J. Liñares1,2*

Microbiology Department, Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL, Barcelona, Spain,1 Ciber de Enfermedades Respiratorias, ISCIII, Madrid, Spain,2 Microbiology Department, Hospital Gregorio Marañón, Madrid, Spain,3 Microbiology Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain,4 Infectious Diseases Department, Clinical Research Unit, Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL, Barcelona, Spain5

Received 2 February 2007/ Returned for modification 9 April 2007/ Accepted 26 June 2007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The aim of this study was to analyze the distributions of antibiotic susceptibility patterns, serotypes, phenotypes, genotypes, and macrolide resistance genes among 125 nonduplicated erythromycin-resistant Streptococcus pneumoniae clinical isolates collected in a Spanish point prevalence study. The prevalence of resistance to macrolides in this study was 34.7%. Multiresistance (to three or more antimicrobials) was observed in 81.6% of these strains. Among 15 antimicrobials studied, cefotaxime, moxifloxacin, telithromycin, and quinupristin-dalfopristin were the most active drugs. The most frequent serotypes of erythromycin-resistant isolates were 19F (25%), 19A (17%), 6B (12%), 14 (10%), and 23F (10%). Of the 125 strains, 109 (87.2%) showed the MLSB phenotype [103 had the erm(B) gene and 6 had both erm(B) and mef(E) genes]. Sixteen (12.8%) strains showed the M phenotype [14 with mef(E) and 2 with mef(A)]. All isolates were tested by PCR for the presence of the int, xis, tnpR, and tnpA genes associated with conjugative transposons (Tn916 family and Tn917). Positive detection of erm(B), tet(M), int, and xis genes related to the Tn916 family was found in 77.1% of MLSB phenotype strains. In 16 strains, only the tndX, erm(B), and tet(M) genes were detected, suggesting the presence of Tn1116, a transposon recently described for Streptococcus pyogenes. Five clones, namely, Sweden15A-25, clone19F ST87, Spain23F-1, Spain6B-2, and clone19A ST276, accounted for half of the MLSB strains. In conclusion, the majority of erythromycin-resistant pneumococci isolated in Spain had the MLSB phenotype, belonged to multiresistant international clones, and carried the erm(B), tet(M), xis, and int genes, suggesting the spread of transposons of the Tn916 family.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Streptococcus pneumoniae is an important human pathogen associated with respiratory tract infections, bacteremia, and meningitis (28, 30). Antimicrobial resistance among S. pneumoniae has spread worldwide, and an increase in erythromycin resistance has also been described (21). Data from a global international surveillance project (PROTEKT, 1993-2003) showed an increase in the global rate of macrolide resistance, from 31.0% in 1999 to 36.3% in 2003 (35), but important differences in these rates were found among countries. In Europe in 2003, the highest rates of macrolide resistance were observed in Greece (55.1%), France (54.2%), Italy (41.8%), Belgium (31.3%), and Spain (30.8%), whereas the lowest rates were found in Czech Republic (3.9%), The Netherlands (4.5%), and Sweden (6.8%). In North America, the prevalence of resistance to macrolides was higher in the United States (35.4%) than in Mexico (27.5%) or Canada (14.7%). Most alarming are the resistance rates found in Far East countries, from 68.3% in China to 79.3% in Japan and 91.2% in Taiwan (35). Coresistance to macrolide and beta-lactam antibiotics is a frequent finding among pneumococci of serotypes 6A, 6B, 14, 15A, 19F, 19A, 23F, and 23A, and these multidrug-resistant strains belong to international clones described by the Pneumococcal Molecular Epidemiology Network (26, 33; http://www.sph.emory.edu/PMEN).

Macrolide resistance in S. pneumoniae is mediated mainly by two mechanisms, namely, target site modification and an efflux pump (22). Target site modification by methylases encoded mainly by the erm(B) gene is related to the MLSB phenotype (resistance to macrolide-lincosamide-streptogramin B). The second mechanism is an efflux pump encoded by mef genes and related to the M phenotype (resistance to 14- and 15-membered ring macrolides). Other, less commonly described mechanisms are mutations in the 23S rRNA gene and/or alterations in riboproteins L4 and L22 (22). In Spain (31) and the majority of European countries, the MLSB phenotype is dominant, whereas the M phenotype is more frequent in England (1), Germany (33), the United States (13), and Canada (32).

In pneumococci and related streptococci, the frequent association of erythromycin and tetracycline resistance is related to transposons such as Tn1545, Tn3872, and Tn6002, resulting from the insertion of the erm(B) gene into the Tn916 family of conjugative transposons that harbor the tet(M) gene (5, 9, 34). Tn916 is a well-known transposon that carries the tet(M) gene and has the int gene (integrase) and the xis gene (excisionase), which encode transposition functions.

The efflux pump mechanism in pneumococci is codified by three subclasses of mef(A) genes, including mef(E), mef(A), and the recently described subclass mef(I) (8). The mef(E) gene is the most frequently found and is carried by the macrolide efflux genetic assembly (mega) element, whereas mef(A) is carried by a defective transposon (Tn1207.1) and is mainly associated with the England14-9 clone (1, 11). Recently, two new composite elements of the Tn916 family, containing the tet(M) gene plus mega (Tn2009) and the tet(M) and erm(B) genes plus mega (Tn2010), have been described (12).

The aim of this study was to analyze the distributions of antibiotic susceptibility patterns, serotypes, phenotypes, genotypes, and macrolide resistance genes among 125 nonduplicated erythromycin-resistant Streptococcus pneumoniae clinical isolates collected in a Spanish point prevalence study.

(This work was presented in part at the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 1 to 4 April 2006 [5a].)


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Bacterial strains. A multicenter point prevalence study was carried out in Spain during a 1-week period (16 to 22 February 2004), with 147 Spanish hospitals enrolled. Three hundred sixty Streptococcus pneumoniae isolates were collected from clinical samples from 112 centers (4). One hundred twenty-five (34.7%) of them were erythromycin resistant and were analyzed in this study. Thirty-three strains (26.4%) were isolated from invasive sites (22 blood, 6 cerebrospinal fluid, 2 peritoneal fluid, 1 joint fluid, 1 pleural fluid, and 1 aqueous humor sample), and 92 (73.6%) were isolated from noninvasive sites (54 upper respiratory tract, 16 middle ear fluid, 11 conjunctiva, 9 nasopharyngeal exudate, and 2 sinus exudate samples). S. pneumoniae isolates were identified by bilis solubility and optochin susceptibility. Serotyping was carried out by the Quellung reaction and/or dot blot assay, with the use of antisera provided by the Statens Seruminstitute (Copenhagen, Denmark), as described previously (17, 18).

Antibiotic susceptibility testing. MICs were determined for all pneumococcal strains by the microdilution method with Mueller-Hinton broth containing 2 to 5% lysed horse blood according to the CLSI method (7), using commercially available panels (STRHAE1; Sensititre, West Sussex, England). MICs of telithromycin were determined by a microdilution method by using commercially available panels (EMIZAQS; Sensititre, West Sussex, England). S. pneumoniae ATCC 49619 was used for quality control. The following antibiotics (range of dilutions) were tested: penicillin (0.03 to 8 µg/ml), amoxicillin-clavulanic acid (0.5/0.25 to 8/4 µg/ml), cefotaxime (0.06 to 4 µg/ml), erythromycin (0.25 to 32 µg/ml), azithromycin (0.5 to 4 µg/ml), josamycin (0.5 to 2 µg/ml), clindamycin (0.25 to 0.5 µg/ml), levofloxacin (0.5 to 4 µg/ml), moxifloxacin (0.25 to 1 µg/ml), trimethoprim-sulfamethoxazole (0.5/9.5 to 2/38 µg/ml), chloramphenicol (2 to 8 µg/ml), tetracycline (2 to 4 µg/ml), vancomycin (0.25 to 8 µg/ml), quinupristin-dalfopristin (1 to 2 µg/ml), and telithromycin (0.015 to 32 µg/ml). Interpretative criteria for josamycin are not given by the CLSI (6), and thus we used the breakpoints for josamycin given by the Société Française de Microbiologie (www.sfm.asso.fr). Kanamycin resistance was detected by disk diffusion using standard disks with 1 mg of kanamycin, and interpretive criteria were according to the Société Française de Microbiologie (www.sfm.asso.fr). Telithromycin resistance was also studied by the disk diffusion method by using standard disks with 15 µg of telithromycin.

Phenotypic characterization of macrolide resistance was performed by the double-disk diffusion method, using standard disks of erythromycin (15 µg) and clindamycin (2 µg). Inducible resistance to clindamycin was detected by placing the clindamycin disk 12 mm from the edge of the erythromycin disk. After incubation, organisms that showed flattening of the clindamycin zone adjacent to the erythromycin disk ("D zone") had an inducible macrolide resistance phenotype, whereas those strains that had a conserved inhibition zone with the clindamycin disk were considered to have the M phenotype (6). The tetracycline susceptibility of tetracycline-susceptible strains harboring the tet(M) gene was confirmed by determining MICs, with and without tetracycline induction (0.05 µg/ml), as described previously (5).

Detection of resistance genes. Macrolide resistance genes [erm(B), erm(A) subclass erm(TR), and mef(A/E)] were detected by PCR, using previously described primers and conditions (37). The PCR products of the mef gene were digested with BamHI (Invitrogen) in order to discriminate between the mef(A) and mef(E) gene subclasses (27). This approach was unable to differentiate between mef(I) and mef(E) genes (8).

The tetracycline resistance gene tet(M) and the promoter of the aph3'-III gene were studied by PCR by using previously described primers and conditions (1, 19). To investigate the presence of the Tn916 family of transposons, the int and xis genes associated with this family of transposons were studied by PCR as previously described (1, 5). The presence of tnpA and tnpR genes related to the Tn917 transposon was detected by PCR as previously described (5). Strains with a negative PCR result for all four genes related to Tn916 or Tn917 were tested for the presence of the resolvase gene (tndX) of Tn5397 (a defective Tn916-related transposon) as described previously (5).

Typing methods. All erythromycin-resistant strains were typed by pulsed-field gel electrophoresis (PFGE). Genomic DNA embedded in agarose plugs was restricted with SmaI, fragments were separated by PFGE as described previously, and PFGE patterns were compared with those of clones established by the Pneumococcal Molecular Epidemiology Network (26).

Multilocus sequence typing (MLST) was performed for selected strains of each dominant PFGE pattern as described previously (14). One representative strain of each dominant PFGE pattern was selected for MLST. In addition, a representative strain of each serotype was studied for those clones showing capsular switching. The allele numbers and sequence types (STs) were assigned using the pneumococcal MLST website (http://www.mlst.net), which is maintained at Imperial College London and funded by the Wellcome Trust.

Statistical analysis. Data were recorded and stored in a database. All statistical analysis was performed using SPSS, version 10.0 (SPSS, Chicago, IL). The {chi}2 test was used for statistical analysis, with Yates's correction when appropriate.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Susceptibility test and serotype distribution. The rate of erythromycin resistance among pneumococci recovered in the point prevalence multicenter study was 34.7% (125/360 isolates). Among the 125 Eryr isolates, 45 were recovered from children (31 isolates from ≤2-year-old children, 10 from 3- to 5-year-old children, and 4 from 6- to 15-year-old children) and 80 were recovered from adults (40 isolates from 16- to 64-year olds and 40 isolates from ≥65-year-old adults). No statistically significant difference was found among the erythromycin resistance rates for pneumococci isolated from children (40.9% [45/110 isolates]) and from adults (32.0% [80/250 isolates]) (P = 0.1). However, strains isolated from ≤2-year-old children had a higher erythromycin resistance rate (68.9% [31/45 isolates]) than did those found in adults (32.0% [80/250 isolates]) (P < 0.01) or 6- to 15-year-old children (19.1% [4/21 isolates]) (P < 0.01). Similar rates of erythromycin resistance were found among invasive and noninvasive pneumococci (33/110 isolates [30.0%] versus 92/250 isolates [36.8%]; P = 0.1). The rate of erythromycin resistance was significantly greater among penicillin-resistant than among penicillin-susceptible strains (62.8% [93/148 isolates] versus 15.1% [32/212 isolates]; P < 0.001). The erythromycin-resistant isolates were associated with significantly higher rates of resistance to penicillin (74.4% [93/125 isolates] versus 27.6% [65/235 isolates]), tetracycline (80.0% [100/125 isolates] versus 27.6% [65/235 isolates]), chloramphenicol (34.4% [43/125 isolates] versus 4.6% [11/235 isolates]), and cotrimoxazole (68.8% [86/125 isolates] versus 32.3% [76/235 isolates]) (P < 0.001 for all comparisons) than were erythromycin-susceptible isolates. Multiresistance (to ≥3 antimicrobials) was observed in 81.6% of strains. All strains were susceptible to telithromycin, with MICs ranging from 0.03 to 0.5 µg/ml. Table 1 shows the in vitro activities of 15 antimicrobials against 125 erythromycin-resistant pneumococci. Cefotaxime and moxifloxacin showed good activity against multiresistant strains, but only telithromycin, quinupristin-dalfopristin, and vancomycin were active against all strains tested. Telithromycin was the most active of the antimicrobials tested against S. pneumoniae, irrespective of patient age or the origin of the specimen. Kanamycin resistance was found in 10 (8.0%) strains. Of 125 erythromycin-resistant pneumococci, 109 (87.2%) showed an MLSB phenotype and 16 (12.8%) showed an M phenotype. The rate of the M phenotype was higher among pneumococci isolated from children under 2 years old (7/31 isolates [22.5%]) than among pneumococci isolated from adults (8/80 isolates [10%]), although the difference was not statistically significant (P = 0.08).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Antimicrobial susceptibilities of 125 erythromycin-resistant S. pneumoniae strains

 
Using the double-disk test, 16 isolates showed an M phenotype, 91 isolates showed a constitutive MLSB phenotype, and 18 showed an inducible MLSB phenotype (Table 2). These 18 strains showed flattening of the clindamycin zone adjacent to the erythromycin disk (D zone). The MICs of erythromycin for 18 inducible MLSB isolates ranged from 4 to >32 µg/ml, the MICs of clindamycin ranged from 0.5 to >0.5 µg/ml, and the MICs of josamycin were all >2 µg/ml. After induction with erythromycin at a subinhibitory concentration (0.05 µg/ml), all of the inducible MLSB strains showed an increase in clindamycin MICs, and a subpopulation of resistant colonies in the inhibition zone or no inhibition zone was observed when erythromycin and clindamycin were tested again by the double-disk diffusion method.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Distributions of phenotypes, genotypes, and antimicrobial resistance patterns of 125 erythromycin-resistant S. pneumoniae isolates

 
Table 2 shows the relationships among erythromycin resistance phenotypes, MICs of erythromycin, clindamycin, and josamycin, resistance patterns, and macrolide and tetracycline resistance genes. Although 17 resistance patterns were found, 2 of them (Penr Eryr Clir Chlr SxTr Tetr and Penr Eryr Clir SxTr Tet) accounted for 49.6% of resistant strains. The majority (45%) of strains with these two resistance patterns belonged to serotype 19F.

Eighteen serotypes were found among erythromycin-resistant strains (Table 3). Five of them (19F [25%], 19A [17%], 6B [12%], 14 [10%], and 23F [10%]) accounted for 74% of all isolates. Among MLSB phenotype strains, 64% belonged to serotypes 19F, 19A, 6B, 23F, 15A, and 14, whereas the M phenotype strains belonged mainly to serotype 14 (8 of 16 strains).


View this table:
[in this window]
[in a new window]

  		TABLE 3. Phenotypes and genotypes among 125 erythromycin-resistant S. pneumoniae isolates

 
Gene detection. No erm(A) subclass erm(TR) methylase gene was detected among the 125 isolates studied. No erythromycin-resistant pneumococci were mef and erm(B) negative. Table 3 shows the associations among genotypes, serotypes, and clones. The erm(B) gene was detected in all 109 MLSB isolates; 6 of them harbored both erm(B) and mef(E) genes and were isolated from five adults and one child. These six strains belonged to five serotypes (19A [two isolates], 19F, 23F, 24, and 33) and were not clonally related.

MLSB phenotype isolates with resistance to tetracycline. The association of tetracycline and erythromycin resistance was found in 100 (91.7%) isolates with the MLSB phenotype (Table 3). The tet(M) gene was detected in all of them. Twenty-seven (27.0%) tetracycline-resistant strains had int, xis, tnpA, and tnpR genes related to Tn3872, and 4 of these 27 isolates also carried other genes [three harbored the aph3'-III gene and one had a mef(E) gene]. Seven isolates with int and xis genes showed kanamycin resistance and positive detection of the promoter of the aph3'-III gene by PCR, and one of them also carried a mef(E) gene. This combination of genes [erm(B), tet(M), int, xis, and aph3'-III] is characteristic of Tn1545, a Tn916-related transposon. Forty-nine (49%) isolates had int and xis genes and could be related to Tn6002, and three of them also carried the mef(E) gene. The xis, int, tnpA, and tnpR genes were not detected by PCR in the remaining 17 isolates. The tndX gene, a resolvase gene of a defective variant of the Tn916 transposon (Tn5397), was detected in 16 of these 17 isolates, suggesting the presence of Tn1116, a transposon recently described for Streptococcus pyogenes (5).

MLSB phenotype isolates with susceptibility to tetracycline. Five of nine tetracycline-susceptible isolates had the erm(B), int, and xis genes. Three of the four remaining isolates had the erm(B) gene alone. The last isolate had int, xis, tnpA, tnpR, erm(B), mef(E), and tet(M) genes and was of serotype 19A (Table 3). After induction with subinhibitory concentrations of tetracycline (5), no variations in tetracycline MIC were found for this tetracycline-susceptible tet(M)-positive isolate, suggesting the presence of a silent form of the tet(M) gene.

M phenotype isolates. Fourteen (87.5%) of 16 M phenotype isolates harbored the mef(E) gene, and 2 (12.5%) harbored the mef(A) gene. One mef(E) isolate was also resistant to tetracycline and harbored the tet(M), xis, and int genes. No tet(M), xis, and int genes were detected by PCR in the remaining 15 tetracycline-susceptible isolates.

Molecular typing (PFGE and MLST). Forty-nine different PFGE patterns were found among 109 MLSB isolates (Table 3). Five of them (Sweden15A-25, clone19F-C, Spain23F-1, Spain6B-1, and clone19A-Z) accounted for 51.4% of the MLSB isolates. Among 16 M phenotype isolates, 10 different PFGE patterns were found, but two clones (Spain9V-3 and England14-9) accounted for half of the isolates.

Capsular switching was observed in three international clones, namely, Spain9V-3, Sweden15A-25, and Spain23F-1. All strains of the Spain9V-3 clone showed capsular switching and were serotype 14. Only 4 of 14 strains of Sweden15A-25 had serotype 15A, and the remaining 10 strains showed capsular switching (8 were serotype 19F and 2 were serotype 19A). The majority of strains (8/12 strains) of clone Spain23F-1 were serotype 23F, and only four strains had capsular switching (three were serotype 19F and one was serotype 19A).

To assess the identities of major PFGE patterns with global clones, 14 representative isolates of major PFGE patterns were selected for MLST (Table 4). Three isolates of the Sweden15A-25 clone were related to CC63, with two single-locus variants (SLV) (ST374 and ST2100). Clone19A-Z was related to ST276 (SLV of Denmark14-32). Clone23A-Y was related to ST42, a double-locus variant (DLV) of Tennessee23F-4. Clone19A-O was related to ST202, a DLV of Taiwan19F-14. Clone19F-C was related to ST87.


View this table:
[in this window]
[in a new window]

  		TABLE 4. Properties of erythromycin-resistant strains selected for MLST

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our results show a high prevalence of resistance to macrolides in pneumococci isolated in 2004 in Spain, in agreement with previous studies (18, 31). A progressive increase in the rate of erythromycin resistance has been observed in Spain over the last 2 decades: while in 1979-1980 the pneumococcal macrolide resistance rate was 0% (23), the rate had increased to 4.3% by 1981-1989 (23), to 22.5% in 1990-1996 (18), and to 34.5% in 2001-2002 (31). Although the prevalence of resistance to macrolides in S. pneumoniae varies substantially among countries, the increase of macrolide-resistant pneumococci is a worldwide problem (20, 35). In Europe, the Mediterranean countries (France, Greece, Italy, and Spain) have the highest rates of erythromycin-resistant pneumococci, while the lowest resistance rates are found among northern European countries (35). These differences probably reflect variations in macrolide consumption rates (European Surveillance of Antibiotic Consumption [http://www.ua.ac.be/esac]) and the spread of multiresistant clones.

The present study shows that erythromycin-resistant isolates were associated with significantly higher rates of resistance to penicillin, tetracycline, chloramphenicol, and cotrimoxazole than were erythromycin-susceptible isolates. However, cefotaxime with in vitro activity against 98% of multiresistant pneumococci tested in this study remains a therapeutic option for nonmeningeal invasive pneumococcal infections caused by strains with MICs of ≤2 µg/ml (30). The resistance rates among new fluoroquinolones remained low (moxifloxacin, 2.4%; and levofloxacin, 4%). However, it is important that three strains susceptible to levofloxacin and moxifloxacin, but with ciprofloxacin MICs of 4 to 8 µg/ml, had an S79F change in ParC (data not shown), and it is well known that the development of fluoroquinolone-resistant strains during therapy is usually associated with strains with first-step mutations that were apparently susceptible to new fluoroquinolones (10). The ketolide telithromycin was active against all isolates tested, harboring the erm(B) gene and/or mef gene, inhibiting 90% of isolates at 0.25 µg/ml, in agreement with previous reports (2, 16, 35). Vancomycin and quinupristin-dalfopristin resistance was not detected among macrolide-resistant isolates.

The present study, in addition to others (26, 33), shows that resistance to macrolides and other antimicrobials is associated with the spread of multiresistant international clones of S. pneumoniae (http://www.sph.emory.edu/PMEN). Since the 1980s, penicillin resistance has been common in Spain (18, 23, 31) and has been related to the following five clones: Spain23F-1, Spain6B-2, Spain9V-3, Spain14-5, and clone19F-ST87 (10, 14, 15, 39). All of these clones have already been associated with erythromycin and multidrug resistance (2, 3, 10, 24).

Sweden15A-25 (ST63) is a worldwide disseminated clone that usually shows capsular switching with different serotypes (14, 19A, 19F, and 23F) (www.mlst.net). In our study, the Sweden15A-25 clone was the most frequently found clone among erythromycin-resistant pneumococci, with 14 isolates, and the majority of isolates showed capsular switching (serotype 19F or 19A). This clone has been described in Spain as a cause of meningitis (15) and among multidrug- and ciprofloxacin-resistant strains (10). Clone19F-ST87, the second in frequency, with 13 isolates, has been described previously in Spain (10, 15), Portugal, and Italy (www.mlst.net). The third and fourth most frequent clones were Spain23F-1 and Spain6B-2, with 12 isolates and 9 isolates, respectively. These two major clones have been prevalent in Spain in the last 2 decades (18). However, since the introduction of a seven-valent pneumococcal conjugated vaccine (PCV7) in 2001, a significant decrease in Spain23F-1 and Spain6B-2 clones has been observed in Spain (unpublished data). Clone19A-ST276, an SLV of the Denmark14-32-ST230 clone, ranked fifth in the present study. This clone has been found in other European countries, associated with serotypes/groups 14, 19, 20, 23, and 24 (www.mlst.net).

Serotypes 19F and 19A were the most frequently found serotypes among erythromycin-resistant pneumococci in this study. It is important that the majority of these isolates belonged to international clones (Sweden15A-25, Denmark14-32, and Spain23F-1) as a result of capsular switching. These findings are in agreement with the work of Pai et al. (29), who reported an increase in the rates of infection caused by multiresistant serotype 19A pneumococci in the United States in the post-PCV7 period (2003-2004). They suggest that this increase in the rates of infection with serotype 19A may be due, in part, to serotype switching within vaccine serotype strains.

The MLSB phenotype is prevalent in the majority of European countries, whereas the M phenotype predominates in North America (13, 32) and some European countries (England and Germany) (1, 33). Our study shows that macrolide-resistant pneumococci in Spain are associated mainly with the MLSB phenotype, as previously reported (31, 33). However, in recent years, a significant increase in the M phenotype has been observed in Spain, from 3.3% of strains in 1998 to 8.9% of strains in 2003, associated with isolates of the serotype 14 variant of the Spain9V-3 clone harboring the mef(E) gene (2, 3). An increase in the rate of the M phenotype (up to 12.8%) was observed in the present study, performed in 2004. This finding is in contrast with the increase of the M phenotype related to the England14-9 clone harboring the mef(A) gene observed in Germany (38).

A worldwide emergence of pneumococci harboring both erm(B) and mef(E) genes has been described (16), with a global prevalence of 16.4% among macrolide-resistant isolates. The association of erm(B) and mef(E) genes has been related to the clonal spread of the Taiwan19F-14 clone and, less frequently, to dissemination of Taiwan23F-15 and Spain23F-1 clones. In the present study, we found only six (5.5%) isolates that harbored both genes, but no clonal relationship among these strains was found.

Tetracycline and macrolide resistances are usually associated because the tet(M) and erm(B) genes are located in transposons of the Tn916 family (9, 34). In agreement with this, we found that more than 90% of MLSB strains were resistant to tetracycline and harbored both erm(B) and tet(M) genes. Our data suggest that the majority of erythromycin- and tetracycline-resistant strains could carry Tn6002, a Tn916-related transposon that harbors the erm(B) gene. This transposon has been detected in Streptococcus cristatus and S. pyogenes (5). The second most frequent combination of genes (int, xis, tnpA, and tnpR) found in this study could indicate the presence of Tn3872. This element is frequently found in pneumococci and other clinically significant streptococci (5, 19, 36) and is the result of the integration of Tn917 into Tn916 (25). Kanamycin resistance is related to Tn1545, a Tn916 family element that acquired erm(B) and aph3'III genes. In agreement with the observations of other authors (19, 25, 36), a low prevalence of kanamycin resistance (8.0%) was detected among erythromycin- and tetracycline-resistant pneumococci.

No detection of int, xis, tnpA, and tnpR genes was observed in our study among isolates of the Sweden15A-25 clone. However, all strains of this clone harbored erm(B), tet(M), and tndX genes. This combination of genes could be related to Tn1116, which was recently described for S. pyogenes (5). Tn1116 is a composite structure resulting from the acquisition of the erm(B) gene by the Tn916-related defective transposon Tn5397, in which a resolvase gene (tndX) replaces the functions of the int and xis genes (5).

In conclusion, the high prevalence of macrolide resistance in Spain is due mainly to the dissemination of multiresistant pneumococcal clones and to the horizontal spread of the Tn916 family of transposons. Further surveillance studies are needed to understand the epidemiology of macrolide-resistant pneumococci and to evaluate the impact of PCV7 in serotype and clone distributions.


   ACKNOWLEDGMENTS
 
This work was supported by two grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social (PI 020269 and PI060647), by the Spanish Pneumococcal Infection Study Network G03/103 (Red Temática de Cooperación del FIS), and by Ciber de Enfermedades Respiratorias (CB06/06/0037; Ministry of Health, Instituto de Salud Carlos III, Madrid, Spain).


   FOOTNOTES
 
* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Universitario de Bellvitge, Feixa Llarga S/N 08907, L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 34 932607930. Fax: 34 932607547. E-mail: fina.linares{at}csub.scs.es Back

{triangledown} Published ahead of print on 2 July 2007. Back


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Amezaga, M. R., P. E. Carter, P. Cash, and H. McKenzie. 2002. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J. Clin. Microbiol. 40:3313-3318.[Abstract/Free Full Text]
  2. Ardanuy, C., F. Tubau, J. Liñares, M. A. Domínguez, R. Pallarés, R. Martín, and the Spanish Pneumococcal Infection Study Network (G03/103). 2005. Distribution of subclasses mef(A) and mef(E) of the mef(A) gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes. Antimicrob. Agents Chemother. 49:827-829.[Abstract/Free Full Text]
  3. Ardanuy, C., A. Fenoll, S. Berrón, L. Calatayud, and J. Liñares. 2006. Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone. Antimicrob. Agents Chemother. 50:3162-3165.[Abstract/Free Full Text]
  4. Bouza, E., C. Arenas, E. Cercenado, O. Cuevas, D. Vicioso, and A. Fenoll. 2007. Microbiologic workload and clinical significance of Streptococcus pneumoniae isolated during one week in Spain. Microb. Drug Resist. 13:52-61.[CrossRef][Medline]
  5. Brenciani, A., A. Bacciaglia, M. Vecchi, L. A. Vitali, P. E. Varaldo, and E. Giovanetti. 2007. Genetic elements carrying erm(B) in Streptococcus pyogenes and association with tet(M) tetracycline resistance gene. Antimicrob. Agents Chemother. 51:1209-1216.[Abstract/Free Full Text]
  6. Calatayud, L., C. Ardanuy, E. Cercenado, A. Fenoll, E. Bouza, R. Pallares, R. Martín, and J. Liñares. 2006. Abstr. 16th Eur. Cong. Clin. Microbiol. Infect. Dis., Nice, France, 1 to 4 April 2006, abstr. P1815.
  7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
  8. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 7th ed. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
  9. Cochetti, I., M. Vecchi, M. Mingoia, E. Tili, M. R. Catania, A. Manzin, P. E. Varaldo, and M. P. Montanari. 2005. Molecular characterization of pneumococci with efflux-mediated erythromycin resistance and identification of a novel mef gene subclass, mef(I). Antimicrob. Agents Chemother. 49:4999-5006.[Abstract/Free Full Text]
  10. Courvalin, P., and C. Carlier. 1987. Tn1545: a conjugative shuttle transposon. Mol. Gen. Genet. 206:259-264.[CrossRef][Medline]
  11. de la Campa, A. G., L. Balsalobre, C. Ardanuy, A. Fenoll, E. Pérez-Trallero, J. Liñares, and the Spanish Pneumococcal Infection Study Network (G03/103). 2004. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg. Infect. Dis. 10:1751-1759.[Medline]
  12. Del Grosso, M., F. Iannelli, C. Messina, M. Santagati, N. Petrosillo, S. Stefani, G. Pozzi, and A. Pantosti. 2002. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J. Clin. Microbiol. 40:774-778.[Abstract/Free Full Text]
  13. del Grosso, M., R. Cailli, F. Iannelli, G. Pozzi, and A. Pantosti. 2006. The mef(E)-carrying genetic element (mega) of Streptococcus pneumoniae: insertion sites and association with other genetic elements. Antimicrob. Agents Chemother. 50:3361-3366.[Abstract/Free Full Text]
  14. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.[Abstract/Free Full Text]
  15. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.[Abstract]
  16. Enright, M. C., A. Fenoll, D. Griffiths, and B. G. Spratt. 1999. The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain. J. Clin. Microbiol. 37:3210-3216.[Abstract/Free Full Text]
  17. Farrell, D. J., S. G. Jenkins, S. D. Brown, M. Patel, B. S. Lavin, and K. P. Klugman. 2005. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11:851-858.[Medline]
  18. Fenoll, A., I. Jado, D. Vicioso, and J. Casal. 1997. Dot blot assay for serotyping of pneumococci. J. Clin. Microbiol. 35:764-766.[Abstract]
  19. Fenoll, A., I. Jado, D. Vicioso, A. Pérez, and J. Casal. 1998. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J. Clin. Microbiol. 36:3447-3454.[Free Full Text]
  20. Izdebski, R., E. Sadowy, J. Fiett, P. Grzesiowski, M. Gniadkowski, and W. Hryniewicz. 2007. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob. Agents Chemother. 51:1155-1163.[Abstract/Free Full Text]
  21. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, R. N. Gruneberg, and The Alexander Project Group. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.[Abstract/Free Full Text]
  22. Klugman, K. P., and J. R. Lonks. 2005. Hidden epidemic of macrolide-resistant pneumococci. Emerg. Infect. Dis. 11:802-807.[Medline]
  23. Leclercq, R., and P. Courvalin. 2002. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:2727-2734.[Free Full Text]
  24. Liñares, J., R. Pallarés, T. Alonso, J. L. Pérez, J. Ayats, F. Gudiol, P. F. Viladrich, and R. Martín. 1992. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin. Infect. Dis. 15:99-105.[Medline]
  25. Marimón, J. M., L. Iglesias, D. Vicente, and E. Pérez-Trallero. 2003. Molecular characterization of erythromycin-resistant clinical isolates of the four major antimicrobial-resistant Spanish clones of Streptococcus pneumoniae (Spain23F-1, Spain6B-2, Spain9V-3, and Spain14-5). Microb. Drug Resist. 9:133-137.[CrossRef][Medline]
  26. McDougal, L. K., F. C. Tenover, L. N. Lee, J. K. Rasheed, J. E Patterson, J. H. Jorgensen, and D. J. LeBlanc. 1998. Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2312-2318.[Abstract/Free Full Text]
  27. McGee, L., L. McDougal, J. Zhou, B. G. Spratt, F. C. Tenover, R. George, R. Hakenbeck, W. Hryniewicz, J. C. Lefevre, A. Tomasz, and K. P. Klugman. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J. Clin. Microbiol. 39:2565-2571.[Abstract/Free Full Text]
  28. Montanari, M. P., M. Mingoia, I. Cochetti, and P. E. Varaldo. 2003. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J. Clin. Microbiol. 41:428-431.[Abstract/Free Full Text]
  29. Musher, D. M. 1992. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14:801-807.[Medline]
  30. Pai, R., M. R. Moore, T. Pilishvili, R. E. Gertz, C. G. Whitney, B. Beall, and Active Bacterial Core Surveillance Team. 2005. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192:1988-1995.[CrossRef][Medline]
  31. Pallarés, R., O. Capdevila, J. Liñares, I. Grau, H. Onaga, F. Tubau, M. H. Schulze, P. Hohl, and F. Gudiol. 2002. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am. J. Med. 113:120-126.[CrossRef][Medline]
  32. Pérez-Trallero, E., C. Garcia-de-la-Fuente, C. Garcia-Rey, F. Baquero, L. Aguilar, R. Dal-Re, J. García-de-Lomas, and Spanish Surveillance Group for Respiratory Pathogens. 2005. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob. Agents Chemother. 49:1965-1972.[Abstract/Free Full Text]
  33. Powis, J., A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, K. Forward, D. Hoban, A. Simor, D. E. Low, and Canadian Bacterial Surveillance Network. 2004. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48:3305-3311.[Abstract/Free Full Text]
  34. Reinert, R. R., A. Ringelstein, M. van der Linden, M. Y. Cil, A. Al-Lahham, and F. J. Schmitz. 2005. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. J. Clin. Microbiol. 43:1294-1300.[Abstract/Free Full Text]
  35. Rice, L. B. 1998. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob. Agents Chemother. 42:1871-1877.[Free Full Text]
  36. Schito, G. C., and D. Felmingham. 2005. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int. J. Antimicrob. Agents 26:479-485.[CrossRef][Medline]
  37. Seral, C., F. J. Castillo, M. C. Rubio-Calvo, A. Fenoll, C. García, and R. Gomez-Lus. 2001. Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain. J. Antimicrob. Chemother. 47:863-866.[Abstract/Free Full Text]
  38. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
  39. van der Linden, M., A. Al-Lahham, S. Haupts, and R. R. Reinert. 2007. Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany. Antimicrob. Agents Chemother. 51:1830-1834.[Abstract/Free Full Text]
  40. Zhou, J., M. C. Enright, and B. G. Spratt. 2000. Identification of the major Spanish clones of penicillin-resistant pneumococci via the Internet using multilocus sequence typing. J. Clin. Microbiol. 38:977-986.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, September 2007, p. 3240-3246, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00157-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00157-07v1
51/9/3240    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calatayud, L.
Right arrow Articles by Liñares, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calatayud, L.
Right arrow Articles by Liñares, J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS